The data derived from this study served as an early feasibility demonstration of the possibility of the use of the MTAM-HFA as a potential anti-cancer drug screening solution for anti-PD1/PDL1 + X combination therapies for lung cancer cases. This evidence concerns the gene CD274 and lung cancer.